The Magazine for Sleep Professionals
Saturday, May 2, 2026
Emmanuel Mignot, MD, PhD, the Craig Reynolds Professor of Sleep Medicine, is the winner of a 2023 Breakthrough Prize in Life Sciences. He will share the $3 million prize with Masashi Yanagisawa, MD, PhD, of the University of Tsukuba for discovering the causes of narcolepsy and paving the way for […]
Jazz Pharmaceuticals plc announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies (APSS) from June 10-13, 2021. “Jazz continues to be committed to deepening our understanding of sleep disorders and delivering […]
Harmony Biosciences Holdings, Inc. announced the FDA has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first and only treatment approved by the FDA for people with excessive daytime sleepiness or cataplexy associated with narcolepsy that is not scheduled as a controlled […]
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is an oxybate product with […]
Harmony Biosciences, LLC (Harmony) announced yesterday that FDA approved WAKIX®(pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. WAKIX is the first and only treatment approved for patients with narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA). […]
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients […]
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The updated Prescription Drug User […]
Wake Up Narcolepsy, a not-for-profit organization dedicated to supporting Narcolepsy awareness and research has launched a newly redesigned website at http://www.wakeupnarcolepsy.org. You’ll find narcolepsy resources, information, and opportunities to connect as well as updates on their latest events. Sign up for their Los Angeles Narcolepsy Day and our upcoming Online Support […]
Platform presentation highlights open-label, long-term safety and tolerability results, durability of effect over time in both EDS and cataplexy in patients with narcolepsy Harmony Biosciences, LLC (Harmony) recently presented new data on pitolisant at the 7th International Symposium on Narcolepsy in Beverly, MA. Pitolisant is an investigational product that has […]
Innovations in Narcolepsy Awareness Join Project Sleep in Boston for Innovations in Narcolepsy Awareness, a unique one-day event and interactive workshop to empower advocates and advance novel approaches to educating the public about narcolepsy. The meeting will take place on Saturday, Sept. 15, 2018, from 10:00 a.m. to 4:00 p.m […]
